Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing
- Autores
- Engström, Anna; Morcillo, Nora Susana; Imperiale, Belén Rocío; Hoffner, Sven E.; Juréen, Pontus
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Conventional phenotypic drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are laborious and very time-consuming. Early detection of drug-resistant tuberculosis (TB) is essential for prevention and control of TB transmission. We have developed a pyrosequencing method for simultaneous detection of mutations associated with resistance to rifampin, isoniazid, ethambutol, amikacin, kanamycin, capreomycin, and ofloxacin. Seven pyrosequencing assays were optimized for following loci: rpoB, katG, embB, rrs, gyrA, and the promoter regions of inhA and eis. The molecular method was evaluated on a panel of 290 clinical isolates of M. tuberculosis. In comparison to phenotypic DST, the pyrosequencing method demonstrated high specificity (100%) and sensitivity (94.6%) for detection of multidrug-resistant M. tuberculosis as well as high specificity (99.3%) and sensitivity (86.9%) for detection of extensively drug-resistant M. tuberculosis. The short turnaround time combined with multilocus sequencing of several isolates in parallel makes pyrosequencing an attractive method for drug resistance screening in M. tuberculosis.
Fil: Engström, Anna. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia
Fil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Hoffner, Sven E.. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia
Fil: Juréen, Pontus. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia - Materia
-
MYCOBACTERIUM TUBERCULOSIS
PYROSEQUENCING
DRUG RESISTANCE
FIRST AND SECOND LINE DRUGS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/192466
Ver los metadatos del registro completo
id |
CONICETDig_e3f1f8ed4b301788026cd8923dd06a04 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/192466 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencingEngström, AnnaMorcillo, Nora SusanaImperiale, Belén RocíoHoffner, Sven E.Juréen, PontusMYCOBACTERIUM TUBERCULOSISPYROSEQUENCINGDRUG RESISTANCEFIRST AND SECOND LINE DRUGShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Conventional phenotypic drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are laborious and very time-consuming. Early detection of drug-resistant tuberculosis (TB) is essential for prevention and control of TB transmission. We have developed a pyrosequencing method for simultaneous detection of mutations associated with resistance to rifampin, isoniazid, ethambutol, amikacin, kanamycin, capreomycin, and ofloxacin. Seven pyrosequencing assays were optimized for following loci: rpoB, katG, embB, rrs, gyrA, and the promoter regions of inhA and eis. The molecular method was evaluated on a panel of 290 clinical isolates of M. tuberculosis. In comparison to phenotypic DST, the pyrosequencing method demonstrated high specificity (100%) and sensitivity (94.6%) for detection of multidrug-resistant M. tuberculosis as well as high specificity (99.3%) and sensitivity (86.9%) for detection of extensively drug-resistant M. tuberculosis. The short turnaround time combined with multilocus sequencing of several isolates in parallel makes pyrosequencing an attractive method for drug resistance screening in M. tuberculosis.Fil: Engström, Anna. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; SueciaFil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; ArgentinaFil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; ArgentinaFil: Hoffner, Sven E.. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; SueciaFil: Juréen, Pontus. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; SueciaAmerican Society for Microbiology2012-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/192466Engström, Anna; Morcillo, Nora Susana; Imperiale, Belén Rocío; Hoffner, Sven E.; Juréen, Pontus; Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing; American Society for Microbiology; Journal of Clinical Microbiology; 50; 6; 6-2012; 2026-20330095-1137CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.asm.org/doi/10.1128/JCM.06664-11info:eu-repo/semantics/altIdentifier/doi/10.1128/JCM.06664-11info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:44:16Zoai:ri.conicet.gov.ar:11336/192466instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:44:16.781CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
title |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
spellingShingle |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing Engström, Anna MYCOBACTERIUM TUBERCULOSIS PYROSEQUENCING DRUG RESISTANCE FIRST AND SECOND LINE DRUGS |
title_short |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
title_full |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
title_fullStr |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
title_full_unstemmed |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
title_sort |
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing |
dc.creator.none.fl_str_mv |
Engström, Anna Morcillo, Nora Susana Imperiale, Belén Rocío Hoffner, Sven E. Juréen, Pontus |
author |
Engström, Anna |
author_facet |
Engström, Anna Morcillo, Nora Susana Imperiale, Belén Rocío Hoffner, Sven E. Juréen, Pontus |
author_role |
author |
author2 |
Morcillo, Nora Susana Imperiale, Belén Rocío Hoffner, Sven E. Juréen, Pontus |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
MYCOBACTERIUM TUBERCULOSIS PYROSEQUENCING DRUG RESISTANCE FIRST AND SECOND LINE DRUGS |
topic |
MYCOBACTERIUM TUBERCULOSIS PYROSEQUENCING DRUG RESISTANCE FIRST AND SECOND LINE DRUGS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Conventional phenotypic drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are laborious and very time-consuming. Early detection of drug-resistant tuberculosis (TB) is essential for prevention and control of TB transmission. We have developed a pyrosequencing method for simultaneous detection of mutations associated with resistance to rifampin, isoniazid, ethambutol, amikacin, kanamycin, capreomycin, and ofloxacin. Seven pyrosequencing assays were optimized for following loci: rpoB, katG, embB, rrs, gyrA, and the promoter regions of inhA and eis. The molecular method was evaluated on a panel of 290 clinical isolates of M. tuberculosis. In comparison to phenotypic DST, the pyrosequencing method demonstrated high specificity (100%) and sensitivity (94.6%) for detection of multidrug-resistant M. tuberculosis as well as high specificity (99.3%) and sensitivity (86.9%) for detection of extensively drug-resistant M. tuberculosis. The short turnaround time combined with multilocus sequencing of several isolates in parallel makes pyrosequencing an attractive method for drug resistance screening in M. tuberculosis. Fil: Engström, Anna. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia Fil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina Fil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina Fil: Hoffner, Sven E.. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia Fil: Juréen, Pontus. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Swedish Institute for Communicable Disease Control; Suecia |
description |
Conventional phenotypic drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are laborious and very time-consuming. Early detection of drug-resistant tuberculosis (TB) is essential for prevention and control of TB transmission. We have developed a pyrosequencing method for simultaneous detection of mutations associated with resistance to rifampin, isoniazid, ethambutol, amikacin, kanamycin, capreomycin, and ofloxacin. Seven pyrosequencing assays were optimized for following loci: rpoB, katG, embB, rrs, gyrA, and the promoter regions of inhA and eis. The molecular method was evaluated on a panel of 290 clinical isolates of M. tuberculosis. In comparison to phenotypic DST, the pyrosequencing method demonstrated high specificity (100%) and sensitivity (94.6%) for detection of multidrug-resistant M. tuberculosis as well as high specificity (99.3%) and sensitivity (86.9%) for detection of extensively drug-resistant M. tuberculosis. The short turnaround time combined with multilocus sequencing of several isolates in parallel makes pyrosequencing an attractive method for drug resistance screening in M. tuberculosis. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/192466 Engström, Anna; Morcillo, Nora Susana; Imperiale, Belén Rocío; Hoffner, Sven E.; Juréen, Pontus; Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing; American Society for Microbiology; Journal of Clinical Microbiology; 50; 6; 6-2012; 2026-2033 0095-1137 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/192466 |
identifier_str_mv |
Engström, Anna; Morcillo, Nora Susana; Imperiale, Belén Rocío; Hoffner, Sven E.; Juréen, Pontus; Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing; American Society for Microbiology; Journal of Clinical Microbiology; 50; 6; 6-2012; 2026-2033 0095-1137 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://journals.asm.org/doi/10.1128/JCM.06664-11 info:eu-repo/semantics/altIdentifier/doi/10.1128/JCM.06664-11 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
American Society for Microbiology |
publisher.none.fl_str_mv |
American Society for Microbiology |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613393484349440 |
score |
13.070432 |